In 2015, the Global Anti-Aging Products and Therapies market accounted for $140.3 billion; by the year 2021, it is expected to reach $216.52 billion by 2021.
Calico, Human Longevity and Elysium are some of the big names that dominate headlines in the field. However, that is not to say there are no other opportunities for investors interested in the business of longevity. In fact, many public biotech companies are interested in anti-aging. As the world population grows older, many life science companies have seen increased interest in devices and anti-aging technologies, including a push for items focused on health preservation.
Here, the Investing News Network (INN) provides a brief overview of four public anti-aging companies organized by market cap size, and the Global X Longevity Thematic ETF, which is focused on serving the world’s growing population.
1. Prana Biotechnology (NASDAQ:PRAN)
Market cap: $24.22 million; Year-to-date percentage: 75.46 percent; current share price: $2.85
Based in Australia, Prana Biotechnology is a development-stage medical biotech company that’s engaged in research related to Alzheimer’s disease, Huntington disease, Parkinson’s disease and other age-related degenerative disorders.
The company’s lead drug candidate, PBT2, is intended to treat Alzheimer’s and Huntington’s diseases. A New Drug Application for Huntington’s disease in 2016/2017 is planned pending positive trial results.
3. BioTime (NYSEMKT:BTX)
Market cap: $311.56 million; Year-to-date percentage: -22.16 percent; current share price: $2.81
Biotech company BioTime works in the field of regenerative medicine, human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. It develops therapies that are based on stem cell technology and are intended to rebuild cell and tissue function lost due to degenerative diseases and injury. These therapeutics target neurological disorders, cancer, age-related macular degeneration, orthopedic disorders and age-related cardiovascular disease.
4. Nu Skin Enterprises (NYSE:NUS)
Market cap: $3.32 billion; Year-to-date percentage: 31.65 percent; current share price: $62.90
Nu Skin Enterprises is a global direct-selling company that markets personal care and nutritional products in 53 markets across the world. Additionally, Nu Skin Enterprises develops and distributes anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. One such anti-aging nutritional supplement is ageLOC R2, which is designed to recharge and renew the body.
5. Zimmer Biomet Holdings (NYSE:ZBH)
Market cap: $25.27 billion; Year-to-date percentage: 21.28 percent; current share price: $125.32
Zimmer Biomet’s focus is on musculoskeletal healthcare. The company designs, manufactures and markets personalized joint replacement technologies. Zimmer’s range of products include uses in orthopaedic reconstruction, sports medicine, biologics, extremities and trauma, spine, craniomaxillofacial and thoracic products and dental implants.
Global X Longevity Thematic ETF (NASDAQ:LNGR)
Market cap: $5.79 million; Year-to-date percentage: 23.15 percent; current share price: $18.88
Although it is not a single company focused on the business of longevity or anti-ageing, investors should take note of the Global X Longevity Thematic ETF. Started in May 2016, the LNGR ETF provides investors with access to companies focused on increasing lifespans or extending quality of life in advanced age, such as health care, pharmaceuticals, and senior living facilities. LNGR has 99 holdings, 33.72 percent of which are companies in the biotechnology space, and 36.11 percent in health care equipment.
This is an updated version of an article originally published on the Investing News Network in 2017.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.